A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises

drug protocol number
GBT2104-132
drug sponsor
Global Blood Therapeutics (GBT)
drug study
Inclacumab
drug trial site
Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabi
drug status
Completed
drug phase